Actuate Therapeutics (ACTU) Return on Capital Employed (2024 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Return on Capital Employed of 221.24% for Q4 2025, up 62079.0% year-over-year from N/an in Q4 2024, and up 45.81% quarter-over-quarter from 408.23% in Q3 2025.
Actuate Therapeutics (ACTU) Return on Capital Employed (2024 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Return on Capital Employed for 2 consecutive years, with 221.24% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 62079.0% year-over-year to 221.24%; the TTM figure through Dec 2025 stood at 221.24% (up 62079.0% YoY), while the FY2025 annual figure was 376.79%, down 132787.0% from the prior year.
- Return on Capital Employed improved to 221.24% in Q4 2025 per ACTU's latest filing, from 408.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5237.0% in Q3 2024 and bottomed at 842.03% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 7.88% |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | -361.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -221.24% |
| Sep 30, 2025 | -408.23% |
| Jun 30, 2025 | 698.94% |
| Mar 31, 2025 | 1,054.19% |
| Dec 31, 2024 | -842.03% |
| Sep 30, 2024 | 5,237.00% |